GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (BSP:A1RG34) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

argenx SE (BSP:A1RG34) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 2020. Start your Free Trial

What is argenx SE Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.


argenx SE (BSP:A1RG34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (BSP:A1RG34) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.